about
Clinical course and treatment outcomes of Sorsby fundus dystrophy.A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1.SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programmeA 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography.A simple method for in vivo labelling of infiltrating leukocytes in the mouse retina using indocyanine green dye.Structural changes of the choroid in sarcoid- and tuberculosis-related granulomatous uveitis.UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12The Evolution of Teleophthalmology Programs in the United Kingdom: Beyond Diabetic Retinopathy ScreeningReevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiography.Structural and functional changes over time in MacTel patients.A detailed phenotypic description of autosomal dominant cone dystrophy due to a de novo mutation in the GUCY2D gene.Automated retinal image analysis for diabetic retinopathy in telemedicine.Retinal layer location of increased retinal thickness in eyes with subclinical and clinical macular edema in diabetes type 2.ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE-FUNCTION CORRELATION.UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.Optical Coherence Tomography Angiography for Anterior Segment Vasculature Imaging.The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.Quantitative analysis of diabetic macular ischemia using optical coherence tomography.Evaluation of Nonperfused Retinal Vessels in Ischemic Retinopathy.Repeatability and reproducibility of choroidal vessel layer measurements in diabetic retinopathy using enhanced depth optical coherence tomography.UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections.Visual acuity loss in patients with age-related macular degeneration measured using a novel high-pass letter chart.Optical Coherence Tomography Features Of Active And Inactive Retinal Neovascularization In Proliferative Diabetic Retinopathy.Phototoxic maculopathy following uneventful cataract surgery in a predisposed patient.Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease.Genome-wide analyses identify common variants associated with macular telangiectasia type 2.Functional observations in vitamin A deficiency: diagnosis and time course of recovery.Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2.3D printing of the choroidal vessels and tumours based on optical coherence tomography.Optical coherence tomography angiography of foveal hypoplasia.Enhanced resolution and speckle-free three-dimensional printing of macular optical coherence tomography angiography.COMPARING FUNDUS FLUORESCEIN ANGIOGRAPHY AND SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE EVALUATION OF DIABETIC MACULAR PERFUSION.PERIPAPILLARY PACHYCHOROID SYNDROME.FUNDUS-WIDE SUBRETINAL AND PIGMENT EPITHELIAL ABNORMALITIES IN MACULAR TELANGIECTASIA TYPE 2.MACULAR TELANGIECTASIA TYPE 2: Quantitative Analysis of a Novel Phenotype and Implications for the Pathobiology of the Disease.EFFECT OF DARK ADAPTATION AND BLEACHING ON BLUE LIGHT REFLECTANCE IMAGING IN MACULAR TELANGIECTASIA TYPE 2.VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.
P50
Q33337540-85C124E7-26D7-48D4-92B8-832B027743D0Q33563565-3B2469CC-EA1D-490F-A965-0BE7EBF365D2Q33577092-20C01A28-5326-4770-A51C-042C3D1DB20DQ33900535-F96E1B2E-89B0-45DB-A793-D42BD39F366FQ34227470-146E9DF2-AB97-4BCC-B9FA-E1403C8648A3Q35094974-11737FC8-5FE6-4051-9144-72D5460C76BAQ35141669-4E878239-3A36-4C00-9584-31DAFC59E867Q35785469-984964AD-2825-4F51-A2AA-2B150156E58BQ35970046-219DB632-406F-4E50-B991-B108E6ADCB30Q36028992-4815EF78-73AF-481C-AC9C-A0EF8C15739CQ36638958-681639F8-04B2-4202-B987-4E29C7A2C440Q37222342-1B8143D2-CB9A-44E9-84E2-1BDFBD08C2ACQ37506009-D15C41FE-D398-4F8F-A76F-EC7128748171Q37697904-F9843108-52ED-4358-AE52-0A7FD1043399Q38362122-A7CF2405-8EDD-448A-A0B2-2396F60637F4Q38405022-1A2692CA-D278-4FA8-8DC4-563A88E2579EQ38706999-FE78CF63-9245-4D68-84D5-5DA7A2718F6BQ38800295-2F1CFE9E-CF22-495E-8D62-73DE176BA43EQ38994184-0B5F7337-619C-40E1-8F81-EBD9BA8C8233Q39103989-D1672BCC-10F2-4401-898D-07ADFB49C59BQ39278032-3393EA65-1947-4304-BB27-38A00FEFA3A6Q39358202-3F3C9CC7-586E-460A-8B20-19ECB757A040Q39443598-38095307-2798-42D4-A5A4-C9A5BF5339BFQ39876159-ECD8A64A-54EE-48DF-80F8-772E99562706Q40023145-CF270735-1E9F-48E1-9FDD-85B2126606F4Q40249417-D2823546-FAE5-4198-9FEB-E1A147642E8EQ43009518-6AE9E5D3-87E0-4299-8BC9-37F6D76BB088Q46072947-AC2E1092-05AD-4674-BE6A-B1ADB23D0FBAQ46703366-3E39EDB5-33E6-4B3F-BAB6-F437EB49D8BCQ46845206-1D4525B8-A961-4614-B092-91370B6AA1F4Q47957923-99147354-ACB5-47EB-97C8-71133C263CDDQ48118118-ACB9CC3A-B939-487D-801A-8AA56F4628CAQ48190140-DDF85F98-1164-4448-8A7F-462F1FAD50F7Q48316135-9AA8D47A-0184-4255-982B-BB3AE99D7CA7Q49965913-4BB4BA3F-8A03-42D7-B8AC-0D0930D39623Q50027615-7AD148DC-9447-4341-9970-6766F49DE47CQ50089121-1AC958B8-35D1-462B-9249-73439030803FQ50158061-7C060FD8-58AB-42CE-89B9-999B470EC42FQ50168307-8C695181-04FB-439B-AAF0-0B841208756DQ50730097-F44FE86E-A643-4FB5-B838-AF7895BC6991
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catherine A Egan
@ast
Catherine A Egan
@en
Catherine A Egan
@es
Catherine A Egan
@nl
type
label
Catherine A Egan
@ast
Catherine A Egan
@en
Catherine A Egan
@es
Catherine A Egan
@nl
prefLabel
Catherine A Egan
@ast
Catherine A Egan
@en
Catherine A Egan
@es
Catherine A Egan
@nl
P106
P21
P31
P496
0000-0001-5593-1169